SSX2 and synovial sarcoma: SSX2 may, therefore, be a target in synovial sarcomas, which were SSX2-positive in 25% in our study and which are treated with SSX2-directed cytotoxic T-lymphocytes in the TACTASOM trial (NCT02239861).